Regeneron has joined the data syndication program for Koneksa‘s LEARNS study that’s assessing the potential of digital biomarkers for measuring the progression of Parkinson’s disease. The program enables Regeneron to gain immediate and continuous access
A newly developed biosensor that can rapidly detect and quantify levels of dopamine — a chemical messenger nerve cells use to communicate — may serve as a low-cost and efficient tool to diagnose and monitor
Understanding and identifying epigenetic changes — those that affect gene activity without altering a gene’s DNA sequence — in blood samples from people with Parkinson’s disease and other neurological conditions may help assess the risk
A Phase 1 trial of ALX-001, an investigational therapy for neurodegenerative conditions, has dosed the first patient with Parkinson’s disease. The clinical trial (NCT06309147) is assessing the safety of Allyx Therapeutics‘ ALX-001 versus a placebo when given
Having difficulty recognizing and describing emotions may be associated with cognitive issues and with mood disorders such as depression, apathy, and impulse control problems in people with Parkinson’s disease, a review study suggests. As a